There are currently 113 ongoing clinical trials involving Malaria
Of the 113 trials,35 trials are in Phase II
Furthermore, 26 trials are in Phase IV
The global pharmaceutical industry is steadily developing new drugs for Malaria, an Infectious disease. The largest number of ongoing clinical trials for Malaria is conducted in the Middle East and Africa region. Asia-Pacific and Europe are among some of the other prominent regions engaged in Malaria-related drug trials.
University of Oxford: The leading ongoing Malaria related clinical trial sponsor
University of Oxford is the top sponsor for Malaria-related ongoing clinical trials.
The National Institute of Allergy and Infectious Diseases, London School of Hygiene & Tropical Medicine, University of California San Francisco, Novartis AG, and Doctor Heitor Vieira Dourado Foundation for Tropical Medicine are among other notable clinical trial sponsors involved in Malaria. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Malaria
Plasmodium falciparum and Hepatitis B vaccine (Mosquirix, GSK-257049, RTS,S/AS01), Tafenoquine succinate (Krintafel, Kozenis, Kodatef), and Doxycycline hyclate (Acticlate) are among the key marketed drugs involving Malaria.
Plasmodium falciparum and Hepatitis B vaccine (Mosquirix, GSK-257049, RTS,S/AS01) is a combination vaccine produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology. GSK-257049 is a pre-erythrocytic vaccine. It limits the ability of Plasmodium falciparum to infect, mature and multiply in the liver by eliciting humoral and cellular immunity to the circumsporozoite protein, which is present at the surface of the sporozoite. It is composed of P. falciparum circumsporozoite protein fused with hepatitis B surface antigen (RTS) portion, and combined with hepatitis B surface antigen (S) in the form of non-infectious virus-like particles (VLPs) and also contains AS01E adjuvant, which is composed of Quillaja saponaria Molina, fraction 21 (QS-21) (25 micrograms) and 3-O-desacyl-4’- monophosphoryl lipid A (MPL) (25 micrograms). Plasmodium falciparum and Hepatitis B vaccine was first approved in 2017 and is marketed in Denmark by GlaxoSmithKline Pharma A/S.
Tafenoquine succinate (Krintafel, Kozenis, Kodatef) is a primaquine analogue, acts as an anti-malarial agent. It functions via DNA Inhibitor mechanism of action It is formulated as film coated tablets for oral route of administration. Krintafel is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection and is indicated for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients aged 16 years and older who are receiving chloroquine for acute P. vivax (blood-stage) infection. Tafenoquine succinate was first approved in 2018 and is marketed in the US, Australia, and Brazil by GlaxoSmithKline LLC.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward